Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591196 | 0.93 | ALDH1A1 (0.32) | ALDH1A1HPGDHTTRAB9A | |
| SCHEMBL589736 | 0.79 | CYP2D6 (0.32) | ALDH1A1HPGD | |
| SCHEMBL590077 | 0.77 | ALDH1A1 (0.33) | ALDH1A1HPGDHTTRAB9A | |
| SCHEMBL3977577 | 0.73 | MTNR1A (0.31) | — | |
| SCHEMBL12666674 | 0.72 | ALDH1A1 (0.34) | ALDH1A1HPGDHTTRAB9A | |
| SCHEMBL591061 | 0.70 | NOS1 (0.38) | — | |
| SCHEMBL592164 | 0.68 | — | — | |
| SCHEMBL591556 | 0.66 | ADRA2C (0.38) | ALDH1A1HTT | |
| SCHEMBL591108 | 0.66 | ADRA2C (0.38) | ALDH1A1HTT | |
| SCHEMBL589723 | 0.66 | ADRA2C (0.38) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120932-B1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-07-09 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | ALDH1A1 1771/4885HPGD 2346/4885HTT 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.